Reuters logo
BRIEF-Inovio Announces Analysis Of VGX-3100 Phase 2b Data
November 29, 2017 / 1:30 PM / 15 days ago

BRIEF-Inovio Announces Analysis Of VGX-3100 Phase 2b Data

Nov 29 (Reuters) - Inovio Pharmaceuticals Inc:

* INOVIO’S FURTHER ANALYSIS OF VGX-3100 PHASE 2B DATA REVEALS IMMUNE CORRELATES AND BIOMARKER SIGNATURES THAT PREDICTED CLINICAL EFFICACY

* INOVIO PHARMACEUTICALS - ‍IN 2018, CO TO INITIATE PHASE 2 “PROOF-OF-CONCEPT” STUDY FOR TREATMENT OF HIGH GRADE ANAL NEOPLASIA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below